Several controversies surround axillary staging of rare breast cancers, especially in the context of next-generation sequencing (NGS) for identifying actionable targets such as PIK3CA mutations, BRCA1/2 mutations, and PD-L1 expression. This evidence concerns the gene CD274 and breast cancer.